DeepMed Research

LEO LABORATORIES LIMITED

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Completed

Conditions: Psoriasis Vulgaris
Plaque Psoriasis

Interventions: Drug: Daivobet® Gel

First Posted Date: 2012-10-16

Last Posted Date: 2018-09-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 561

Registration Number: NCT01707368

Locations: 🇩🇪
PD Dr. med. Rosenbach, Osnabrück, Niedersachsen, Germany

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Ingenol once daily for two consecutive days

First Posted Date: 2012-10-10

Last Posted Date: 2025-02-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 41

Registration Number: NCT01703078

Locations: 🇦🇺
Dermatology Department, Woolloongabba, Queensland, Australia

Cromoglicate in Mastocytosis

Phase 2

Terminated

Conditions: Mastocytosis

Interventions: Drug: Cromoglicate
Drug: Placebo

First Posted Date: 2012-10-05

Last Posted Date: 2025-02-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 7

Registration Number: NCT01701843

Locations: 🇩🇪
Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany

A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris

Phase 2

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
Drug: Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)
Drug: Daivobet® gel applied for 24 hours (+/- 2 hours)
Drug: Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)

First Posted Date: 2012-05-30

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 24

Registration Number: NCT01607853

Locations: 🇫🇷
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Nice, France

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Phase 2

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: LEO 90100

First Posted Date: 2012-05-17

Last Posted Date: 2025-03-07

Lead Sponsor: LEO Pharma

Target Recruit Count: 37

Registration Number: NCT01600222

Locations: 🇨🇦
Guildford Dermatology Specialists, Surrey, British Columbia, Canada
🇨🇦
PerCuro Clinical Research, Victoria, British Columbia, Canada
🇨🇦
Maritime Medical Research Center, Bathurst, New Brunswick, Canada

and more 7 locations

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Ingenol mebutate gel, 0.015%
Drug: Vehicle gel

First Posted Date: 2012-05-16

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 463

Registration Number: NCT01600014

Locations: 🇨🇦
Skin Care Centre, Vancouver, British Columbia, Canada
🇦🇺
St John of God Dermatology, Subiaco, Australia
🇨🇦
Stratica Medical, Edmonton, Alberta, Canada

and more 10 locations

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Phase 1

Completed

Conditions: Psoriasis Vulgaris

First Posted Date: 2012-04-19

Last Posted Date: 2025-03-12

Lead Sponsor: LEO Pharma

Target Recruit Count: 24

Registration Number: NCT01580488

Locations: 🇫🇷
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD) - Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière, Nice, France

Study on Thrombosis Therapy in German Cancer Patients

Completed

Conditions: Cancer
Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Other: no intervention is being made

First Posted Date: 2012-03-21

Last Posted Date: 2014-08-15

Lead Sponsor: LEO Pharma

Target Recruit Count: 76

Registration Number: NCT01559883

Locations: 🇩🇪
Prof. Dr. Axel Matzdorff, Saarbrücken, Saarland, Germany

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Phase 3

Completed

Conditions: Papulopustular Rosacea

Interventions: Drug: Vehicle foam
Drug: Azelaic acid foam, 15% (BAY39-6251)

First Posted Date: 2012-03-15

Last Posted Date: 2023-06-09

Lead Sponsor: LEO Pharma

Target Recruit Count: 961

Registration Number: NCT01555463

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Procedure: Cryotherapy
Drug: Vehicle
Drug: Ingenol metabute

First Posted Date: 2012-03-01

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 367

Registration Number: NCT01541553

Locations: 🇺🇸
Long Island Skin Cancer and Dermatologic Surgery, Smithtown, New York, United States
🇺🇸
Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸
Dermatology Specialists, Inc., Oceanside, California, United States

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy